Published in Antimicrob Agents Chemother on September 01, 2005
Fulminant hepatic failure (FHF) due to acute hepatitis C. Pak J Med Sci (2015) 0.76
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science (1998) 10.43
Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med (2001) 7.71
Viral hepatitis C. Lancet (2003) 5.81
Natural history of recurrent hepatitis C. Liver Transpl (2002) 1.49
Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol (2003) 1.34
Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med (1996) 1.23
Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology (1995) 1.07
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med (2013) 2.84
Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol (2009) 2.23
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol (2006) 2.03
Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol (2008) 1.82
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology (2008) 1.81
Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology (2011) 1.68
Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology (2008) 1.64
A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology (2006) 1.62
A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut (2006) 1.59
Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol (2007) 1.58
Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection. Am J Gastroenterol (2008) 1.54
Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. J Gastroenterol Hepatol (2010) 1.54
OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J (2011) 1.53
A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther (2006) 1.48
Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. J Clin Virol (2013) 1.45
Visfatin--a proinflammatory adipokine-in gallstone disease. Am J Surg (2009) 1.43
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology (2010) 1.38
Incidence and clinical outcome of icteric type hepatocellular carcinoma. J Gastroenterol Hepatol (2002) 1.38
Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol (2007) 1.36
Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis (2010) 1.34
The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int (2011) 1.33
Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther (2005) 1.20
Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol (2011) 1.18
Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol (2011) 1.16
Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol (2009) 1.13
Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol (2007) 1.10
The role of gender on clearance of hepatitis C virus: a different story in an area endemic for hepatitis B and C. Gut (2007) 1.10
Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis (2005) 1.09
Rapid heterogeneous liver-cell on-chip patterning via the enhanced field-induced dielectrophoresis trap. Lab Chip (2006) 1.08
Association between response to pegylated interferon/ribavirin therapy and ribavirin levels. Hepatology (2014) 1.08
Hyperlipidemia in noise-induced hearing loss. Otolaryngol Head Neck Surg (2007) 1.08
The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies. Gut (2007) 1.08
Variants of the inosine triphosphate pyrophosphatase gene and relapse risk following treatment for HCV genotype 2/3. Hepatology (2014) 1.07
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology (2010) 1.07
Intestinal parasitic infection detected by stool examination in foreign laborers in Kaohsiung. Kaohsiung J Med Sci (2010) 1.06
A 24-week pegylated interferon alpha-2b versus a 12-week pegylated interferon alpha-2b alone or with ribavirin for patients with acute hepatitis C. Hepatology (2014) 1.05
Genes responsible for the characteristics of primary cultured invasive phenotype hepatocellular carcinoma cells. Biomed Pharmacother (2012) 1.04
Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci (2010) 1.02
Clinical significance of plasma D-dimer levels and serum VEGF levels in patients with hepatocellular carcinoma. Hepatogastroenterology (2004) 1.02